These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29449645)

  • 21. The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target.
    Qin CD; Ma DN; Zhang SZ; Zhang N; Ren ZG; Zhu XD; Jia QA; Chai ZT; Wang CH; Sun HC; Tang ZY
    Cell Death Dis; 2018 May; 9(5):486. PubMed ID: 29706627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
    Dai N; Ye R; He Q; Guo P; Chen H; Zhang Q
    Oncol Rep; 2018 Dec; 40(6):3235-3248. PubMed ID: 30272354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M; Fei Z; Zhang G
    Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The synergistic antitumor effect of combination therapy with a MEK inhibitor and YAP inhibitor on pERK-positive neuroblastoma.
    Takemoto M; Tanaka T; Tsuji R; Togashi Y; Higashi M; Fumino S; Tajiri T
    Biochem Biophys Res Commun; 2021 Sep; 570():41-46. PubMed ID: 34271435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
    Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells.
    Dai XY; Zhuang LH; Wang DD; Zhou TY; Chang LL; Gai RH; Zhu DF; Yang B; Zhu H; He QJ
    Oncotarget; 2016 Feb; 7(6):6933-47. PubMed ID: 26771844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
    Kim MN; Lee SM; Kim JS; Hwang SG
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment.
    Huang P; Xu X; Wang L; Zhu B; Wang X; Xia J
    J Cell Mol Med; 2014 Feb; 18(2):218-30. PubMed ID: 24268047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SEPT6 drives hepatocellular carcinoma cell proliferation, migration and invasion via the Hippo/YAP signaling pathway.
    Fan Y; Du Z; Ding Q; Zhang J; Op Den Winkel M; Gerbes AL; Liu M; Steib CJ
    Int J Oncol; 2021 Jun; 58(6):. PubMed ID: 33846777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
    Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
    Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous knockdown of YAP and TAZ increases apoptosis of hepatocellular carcinoma cells under hypoxic condition.
    Yan B; Li T; Shen L; Zhou Z; Liu X; Wang X; Sun X
    Biochem Biophys Res Commun; 2019 Jul; 515(2):275-281. PubMed ID: 31146919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
    Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
    Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib.
    Matsuo M; Sakurai H; Ueno Y; Ohtani O; Saiki I
    Cancer Sci; 2006 Feb; 97(2):155-62. PubMed ID: 16441427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioactive components and mechanisms of poplar propolis in inhibiting proliferation of human hepatocellular carcinoma HepG2 cells.
    Liu H; Li J; Yuan W; Hao S; Wang M; Wang F; Xuan H
    Biomed Pharmacother; 2021 Dec; 144():112364. PubMed ID: 34700230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [YAP regulates the proliferation and modifies the sensitivity to sorafenib in hepatocellular carcinoma cells].
    Guo LW; Shao GL; Luo J; Hao WY; Yao Z; Zheng JP
    Zhonghua Zhong Liu Za Zhi; 2018 Nov; 40(11):818-823. PubMed ID: 30481931
    [No Abstract]   [Full Text] [Related]  

  • 36. LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Ma Y; Xu R; Liu X; Zhang Y; Song L; Cai S; Zhou S; Xie Y; Li A; Cao W; Tang X
    Int J Med Sci; 2021; 18(6):1456-1464. PubMed ID: 33628103
    [No Abstract]   [Full Text] [Related]  

  • 37. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of Rac GTPase Activating Protein 1 Contributes to Proliferation of Cancer Cells by Reducing Hippo Signaling to Promote Cytokinesis.
    Yang XM; Cao XY; He P; Li J; Feng MX; Zhang YL; Zhang XL; Wang YH; Yang Q; Zhu L; Nie HZ; Jiang SH; Tian GA; Zhang XX; Liu Q; Ji J; Zhu X; Xia Q; Zhang ZG
    Gastroenterology; 2018 Oct; 155(4):1233-1249.e22. PubMed ID: 30009820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
    Zhou TY; Zhuang LH; Hu Y; Zhou YL; Lin WK; Wang DD; Wan ZQ; Chang LL; Chen Y; Ying MD; Chen ZB; Ye S; Lou JS; He QJ; Zhu H; Yang B
    Sci Rep; 2016 Aug; 6():30483. PubMed ID: 27476430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LncUBE2R2-AS1 acts as a microRNA sponge of miR-302b to promote HCC progression via activation EGFR-PI3K-AKT signaling pathway.
    Wu Z; Wei ZH; Chen SH
    Cell Cycle; 2020 Oct; 19(19):2426-2435. PubMed ID: 32835579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.